Category: Zacks Small Cap Research

1303132333450320 / 500 POSTS
By Steven Ralston, CFAOTC:ALPEREAD THE FULL ALPE RESEARCH REPORTalpha-En Corp (OTC:ALPE) is a technology development company, primarily focusing on the development of a commercially viable process for the production of high-purity lithium metal and o ...
Venture capital is the nexus between entrepreneurs, investment bankers and private investors. These stakeholders scour the investment environment to identify new ideas that are expected to show rapid growth with a modest amount of capital. It is ...
By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Financial UpdateOn July 23, 2018, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) announced financial results for the second quarter of 2018 and provided a business update. As expect ...
By David Bautz, PhD NYSE:OGEN READ THE FULL OGEN RESEARCH REPORT Oragenics, Inc. (NYSE:OGEN) is a biopharmaceutical company developing a new treatment for oral mucositis and novel antibiotic therapies for infectious diseases. The company’s lead devel ...
By Brian Marckx, CFATSX:ZMS.V | OTC:ZMSPFREAD THE FULL ZMS.V RESEARCH REPORTZecotek (TSX:ZMS.V) (OTC:ZMSPF) has had several positive announcements over the last few months, many of which relate to their Chinese operations. Zecotek Imaging China, whic ...
By Lisa Thompson NASDAQ:PIXY READ THE FULL PIXY REPORT HERE ShiftPixy (NASDAQ:PIXY) reported for its FY 2018 Q3 quarter ending May 31, 2018. Q3 gross billings came in at $60.2 million versus $27.5 million a year ago, up 119%, in the middle of th ...
By John Vandermosten, CFANASDAQ:HTBXREAD THE FULL HTBX RESEARCH REPORTINITIATING COVERAGEWe are initiating coverage of Heat Biologics Inc (NASDAQ:HTBX) with a $5.00 price target based on our estimates for a 2023 launch of lead compound HS-110. The cl ...
OTC:ZENOZenosense, Inc. (OTC:ZENO) is a healthcare technology company located in Valencia, Spain.  The company’s main focus is a novel hand-held point-of-care (POC) cardiac diagnostic device called MIDS Cardiac.  Incorporating proprietary sensors and ...
By David Bautz, PhDTSX:ATE.VREAD THE FULL ATE.V RESEARCH REPORTBusiness UpdateSecondary Endpoint Data from Phase 2b Trial of ATB-346On July 3, 2018, Antibe Therapeutics, Inc. (TSX:ATE.V) announced key secondary endpoint data from the company’s Phase ...
By Steven Ralston, CFANASDAQ:IFMKREAD THE FULL IFMK RESEARCH REPORT2018 Fiscal Year ResultsOn June 26, 2018, iFresh (NASDAQ:IFMK) reported financial results for the fiscal year ending March 31, 2018. For the fiscal year, the company reported net sale ...
1303132333450320 / 500 POSTS